Updated Results of ALTER-H006: A Phase II Study of Benmelstobart (PD-L1 Inhibitor) Plus Anlotinib As Adjuvant Therapy in Hepatocellular Carcinoma (HCC) with High Risk of Recurrence after Radical Resection.
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined